In	O
Vivo	O
Deletion	O
of	O
the	O
Cebpa	S-GENE
+	O
37	O
kb	O
Enhancer	O
Markedly	O
Reduces	O
Cebpa	S-GENE
mRNA	O
in	O
Myeloid	O
Progenitors	O
but	O
Not	O
in	O
Non	O
-	O
Hematopoietic	O
Tissues	O
to	O
Impair	O
Granulopoiesis	O
.	O


The	O
murine	O
Cebpa	S-GENE
gene	O
contains	O
a	O
+	O
37	O
kb	O
,	O
evolutionarily	O
conserved	O
440	O
bp	O
enhancer	O
that	O
directs	O
high	O
-	O
level	O
expression	O
to	O
myeloid	O
progenitors	O
in	O
transgenic	O
mice	O
.	O


The	O
enhancer	O
is	O
bound	O
and	O
activated	O
by	O
Runx1	S-GENE
,	O
Scl	S-GENE
,	O
GATA2	S-GENE
,	O
C	B-GENE
/	I-GENE
EBPalpha	E-GENE
,	O
c	B-GENE
-	I-GENE
Myb	E-GENE
,	O
Pu	B-GENE
.	I-GENE
1	E-GENE
,	O
and	O
additional	O
Ets	O
factors	O
in	O
myeloid	O
cells	O
.	O


CRISPR	O
/	O
Cas9	O
-	O
mediated	O
replacement	O
of	O
the	O
wild	O
-	O
type	O
enhancer	O
with	O
a	O
variant	O
mutant	O
in	O
its	O
seven	O
Ets	O
sites	O
leads	O
to	O
20	O
-	O
fold	O
reduction	O
of	O
Cebpa	S-GENE
mRNA	O
in	O
the	O
32Dcl3	O
myeloid	O
cell	O
line	O
.	O


To	O
determine	O
the	O
effect	O
of	O
deleting	O
the	O
enhancer	O
in	O
vivo	O
,	O
we	O
now	O
characterize	O
C57BL	O
/	O
6	O
mice	O
in	O
which	O
loxP	O
sites	O
flank	O
a	O
688	O
bp	O
DNA	O
segment	O
containing	O
the	O
enhancer	O
.	O


CMV	O
-	O
Cre	O
mediated	O
germline	O
deletion	O
resulted	O
in	O
diminution	O
of	O
the	O
expected	O
number	O
of	O
viable	O
Enh	O
(	O
f	O
/	O
f	O
)	O
;	O
CMV	O
-	O
Cre	O
offspring	O
,	O
with	O
28	O
-	O
fold	O
reduction	O
in	O
marrow	O
Cebpa	S-GENE
mRNA	O
but	O
normal	O
levels	O
in	O
liver	O
,	O
lung	O
,	O
adipose	O
,	O
intestine	O
,	O
muscle	O
,	O
and	O
kidney	O
.	O


Cre	O
-	O
transduction	O
of	O
lineage	O
-	O
negative	O
marrow	O
cells	O
in	O
vitro	O
reduced	O
Cebpa	S-GENE
mRNA	O
12	O
-	O
fold	O
,	O
with	O
impairment	O
of	O
granulocytic	O
maturation	O
,	O
morphologic	O
blast	O
accumulation	O
,	O
and	O
IL	B-GENE
-	I-GENE
3	E-GENE
dependent	O
myeloid	O
colony	O
replating	O
for	O
>	O
12	O
generations	O
.	O


Exposure	O
of	O
Enh	O
(	O
f	O
/	O
f	O
)	O
;	O
Mx1	S-GENE
-	O
Cre	O
mice	O
to	O
pIpC	O
led	O
to	O
14	O
-	O
fold	O
reduction	O
of	O
Cebpa	S-GENE
mRNA	O
in	O
GMP	O
or	O
CMP	O
,	O
30	O
-	O
fold	O
reduction	O
in	O
LSK	S-GENE
,	O
and	O
<	O
2	O
-	O
fold	O
reduction	O
in	O
the	O
LSK	S-GENE
/	O
SLAM	S-GENE
subset	O
.	O


FACS	O
analysis	O
of	O
marrow	O
from	O
these	O
mice	O
revealed	O
10	O
-	O
fold	O
reduced	O
neutrophils	O
,	O
3	O
-	O
fold	O
decreased	O
GMP	O
,	O
and	O
3	O
-	O
fold	O
increased	O
LSK	S-GENE
cells	O
.	O


Progenitor	O
cell	O
cycle	O
progression	O
was	O
mildly	O
impaired	O
.	O


Granulocyte	O
and	O
B	O
lymphoid	O
colony	O
forming	O
units	O
were	O
reduced	O
while	O
monocytic	O
and	O
erythroid	O
colonies	O
were	O
increased	O
,	O
with	O
reduced	O
Pu	O
.	O
1	O
and	O
Gfi1	S-GENE
and	O
increased	O
Egr1	S-GENE
and	O
Klf4	S-GENE
in	O
GMP	O
.	O


Finally	O
,	O
competitive	O
transplantation	O
indicated	O
preservation	O
of	O
functional	O
long	O
-	O
term	O
hematopoietic	O
stem	O
cells	O
upon	O
enhancer	O
deletion	O
and	O
confirmed	O
marrow	O
-	O
intrinsic	O
impairment	O
of	O
granulopoiesis	O
and	O
B	O
cell	O
generation	O
with	O
LSK	S-GENE
and	O
monocyte	O
lineage	O
expansion	O
.	O


These	O
findings	O
demonstrate	O
a	O
critical	O
role	O
for	O
the	O
+	O
37	O
kb	O
Cebpa	S-GENE
enhancer	O
for	O
hematopoietic	O
-	O
specific	O
Cebpa	S-GENE
expression	O
,	O
with	O
enhancer	O
deletion	O
leading	O
to	O
impaired	O
myelopoiesis	O
and	O
potentially	O
preleukemic	O
progenitor	O
expansion	O
.	O
